The proteasome inhibitor Velcade enhances rather than reduces disease in mouse hepatitis coronavirus-infected mice.
Raaben M, Grinwis GC, Rottier PJ, de Haan CA.
Raaben M, et al.
J Virol. 2010 Aug;84(15):7880-5. doi: 10.1128/JVI.00486-10. Epub 2010 May 19.
J Virol. 2010.
PMID: 20484516
Free PMC article.
Hence, the proteasome inhibitor Velcade (bortezomib), a clinically approved anticancer drug, shown in an accompanying study (M. Raaben et al., J. Virol. 84:7869-7879, 2010) to strongly inhibit mouse hepatitis CoV (MHV) infection in cultured cells, seemed an attracti …
Hence, the proteasome inhibitor Velcade (bortezomib), a clinically approved anticancer drug, shown in an accompanying study (M. Ra …